Abstract 655P
Background
ADCs are a rapidly emerging modality of systemic anti-cancer treatment with 11 agents FDA approved and more under investigation.
Methods
Patients that received at least 1 dose of ADC in phase 1-3 trials at SCRI UK between 2012-2023 were included. Patient and tumor characteristics, toxicity and outcomes overall and for subgroups of interest were assessed using descriptive statistics and cox regression.
Results
102 patients from 16 trials (8 phase 1, 8 phase 2-3) of 13 different ADCs were included (median age 62 (32-81), male 32.4%). Main tumor types were breast (n=40, 38.5%) and gynecological (n=19, 18.3%). Median number of prior treatment lines was 3 (1-18). Payloads comprised alkylating agents (AA, n=3), microtubule inhibitors (MTI, n=8) or a topoisomerase inhibitor (Topo-I, n=2). 3 ADCs targeted an oncogene (HER2) vs tumor associated antigens (TAA). TRAEs of any grade occurred in 88% of patients (grade 3-4 25%). Colitis occurred in 3.8% (2.9%), ILD 3.8% (1.0%), neuropathy 26.0% (0%), eye toxicity 22.1% (0%) and hepatotoxicity 27.8% (4.8%). Most toxicities occurred early (
Conclusions
ADC activity is seen across different tumors with higher efficacy when oncogene targeted. Identification of timelines of expected toxicities is critical for clinical management and mitigation strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Woodford, A. Cammarota, K. Joshi, R.M. Grochot: Financial Interests, Institutional, Full or part-time Employment: HCA International. A. Williams: Financial Interests, Institutional, Full or part-time Employment: HCA International; Financial Interests, Personal, Advisory Role: Ellipses Pharma UK. E. Fontana: Financial Interests, Personal, Invited Speaker: Caris Life Science, Repair Therapeutics; Financial Interests, Personal, Other, Conference attendance: Sapience Pharma; Financial Interests, Personal, Invited Speaker, Conference Attendance: Bicycles Therapeutics; Financial Interests, Personal, Full or part-time Employment: Hospital Corporation of America (HCA) International; Financial Interests, Personal, Officer: EORTC; Financial Interests, Institutional, Coordinating PI: Repair Therapeutics, Amgen, Taiho Pharmaceutical; Financial Interests, Institutional, Local PI: Bicycle Therapeutics, Artios Pharma, Seagen, Nurix Therapeutics, BioNTech SE, Relay Therapeutics, Pfizer, Roche, Daiichi Sankyo, Gilead Science, Basilea Pharmaceutica, Jiangsu Hengrui Medicine, Mereo Biopharma, Hutchmed, Merus, Crescendo Biologics, GSK plc, BeiGene, Turning Point Therapeutics, Sapience Pharma, Arcus Bioscience, Exelixis, Nerviano Medica, Elipsees, Deciphera, Ribon Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
744P - A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)
Presenter: Jung-Min Lee
Session: Poster session 01
745P - Biomarker-driven targeted therapy in platinum-resistant ovarian cancer (BRIGHT): An open-label, multicenter, umbrella trial
Presenter: Qinglei Gao
Session: Poster session 01
746P - Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression
Presenter: Lan Gardner Coffman
Session: Poster session 01
747P - SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)
Presenter: Clare Scott
Session: Poster session 01
748P - Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma
Presenter: Ana Oaknin
Session: Poster session 01
750P - Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)
Presenter: Claire Friedman
Session: Poster session 01